`571-272-7822
`
`Paper 12
`Entered: December 7, 2020
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SOTERA WIRELESS, INC.,
`Petitioner,
`
`V.
`
`MASIMO CORPORATION,
`Patent Owner.
`
`IPR2020-01078
`Patent RE47,218 E
`
`Before GEORGE R. HOSKINS, JENNIFER MEYER CHAGNON,and
`AMANDAF. WIEKER,Administrative Patent Judges.
`
`HOSKINS,Administrative Patent Judge.
`
`DECISION
`Granting Institution of Inter Partes Review
`35 U S.C. § 314
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`I.
`
`INTRODUCTION
`
`Sotera Wireless, Inc. (“Petitioner”) has filed a Petition (Paper 1,
`
`“Pet.”) pursuant to 35 U.S.C. §§ 311-319 to institute an inter partes review
`of claims 1-10 and 12-18 of U.S. Patent No. RE47,218 E (“the
`
`°218 patent”).
`Masimo Corporation (“Patent Owner”) has filed a Preliminary
`
`Response (Paper6, “Prelim. Resp.”) to the Petition.
`
`Weauthorized additional briefing to address Patent Owner’s argument
`
`that we should denyinstitution under 35 U.S.C. § 314(a) and Apple Inc.v.
`
`Fintiv, Inc., (PR2020-00019, Paper 11 (PTAB Mar. 20, 2020) (precedential)
`
`(‘“Fintiv Order”). See Paper 7. Accordingly, Petitioner filed a Reply
`(Paper 10, “Prelim. Reply”) to the Preliminary Response, and Patent Owner
`filed a Sur-reply (Paper 11, “Prelim. Sur-reply”) to the Reply.
`
`Institution of review requires Petitioner to demonstrate a reasonable
`
`likelihood of prevailing with respect to at least one challenged claim.
`35 U.S.C. § 314(a). Applying that standard on behalf of the Director
`(37 C.F.R. § 42.4(a)), weinstitute an inter partes review to determine
`whether Petitioner demonstrates by a preponderance of the evidence that
`
`claims 1-10 and 12-18 are unpatentable.
`
`Il.
`
`BACKGROUND
`
`A.
`
`Real Parties-in-Interest and Related Proceedings
`
`Sotera Wireless, Inc. and Hon Hai Precision Industry Co., Ltd. are the
`
`real parties-in-interest for Petitioner, and Masimo Corporation is the real
`party-in-interest for Patent Owner. Pet. 1; Paper 5, 1. Also, Masimo Corp.
`v. Sotera Wireless, Inc. and Hon Hai Precision Industry Co. Ltd., Civil
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`Action No. 3:19-cv-01100-BAS-NLS(S.D. Cal.) (“the District Court
`
`Litigation”) is a related judicial matter. Pet. 2; Paper5, 1.
`
`B.
`
`The '218 Patent
`
`The ’218 patent concerns a system for monitoring a patient’s blood
`
`oxygen saturation (SpO2), and generating an alarm if the saturation falls too
`
`low. See Ex. 1001, Abstract, 1:34-39, 2:54-58. The system includes an
`
`optical sensor attached to the patient’s finger, to emit light into the fingertip
`
`tissue and detectlight that is attenuated by blood flow within the fingertip, to
`
`provide a numerical readout of oxygen saturation. See id. at 1:39-55.
`
`Figure 1 of the ’218 patent is reproduced here:
`100
`
`$p02 (%)
`
`£
`
`OFF
`
`ti
`ta
`iT9_,—>|163
`
`t3
`
`14
`
`time
`
`Figure 1 of the ’218 Patent.
`
`Figure 1 illustrates a previously known oxygen saturation measurement
`
`system having two “fixed-threshold alarm” schemes,at “delay” alarm
`
`threshold D, and at “no delay” alarm threshold ND,. Id. at 2:54—-59
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`(emphasis added). If the patient’s measured oxygen saturation 110 falls and
`
`stays below delay threshold D, for a time period greater than time delay TD,
`
`as shown in Figure 1 from timet; to time tz, then delayed alarm 140is
`
`triggered. Id. at 2:59-3:1. If the patient’s measured oxygensaturation 110
`
`falls below no delay threshold ND,, as shownin Figure 1 at time ts, then
`
`immediate alarm 150 is triggered without delay. Jd. at 2:61-62, 3:24.
`
`According to the ’218 patent, the fixed nature of delay alarm
`
`threshold Dy undesirably leadsto “a baseline drift problem,” which can
`
`generate a “nuisance”or “false” alarm. Jd. at 2:54-56, 3:24-46 (describing
`
`Fig. 3). The ’218 patent therefore proposes “an adaptive alarm system,”
`
`whichadjusts the delay alarm threshold downwards when an oxygen
`
`saturation baseline is established at lower values. Jd. at 3:59-62. In this
`
`way, the inventive “alarm threshold .
`
`.
`
`. adapts to baseline drift in [oxygen
`
`saturation] and reduce[s] false alarms without a corresponding increase in
`
`missed true alarms.” Jd. at 4:4-8.
`
`Thisis illustrated in Figure 6 of the ’218 patent, reproduced here:
`
`t 600
`
`Parameter
`610
`
`L
`
`1
`
`—
`
`
`
`ce
`Max fe eee _—-
`
`630
`614
`£ 632
`— BL — parameter
`range
`
`650
`
`t
`l
`
`AT range
`ce
`638
`1
`642
`ce
`AT
`660
`B
`lg — ee He OOOO <0 -a
`648
`46
`
`>6
`
`ty
`S 692
`
`ty
`
`694
`Figure 6 of the ’218 Patent.
`
`ts
`XM 696
`
`G 690
`ume
`
`4
`
`
`
`IPR2020-01078
`Patent RE47,218E
`
`Figure 6 graphs a measured physiological parameter such as oxygen
`
`saturation (the vertical axis) over time (the horizontal axis), as generated by
`
`an alarm system having a lowerlimit adaptive alarm threshold AT. Jd.
`
`at 5:34-36, 7:40-47. An adaptive alarm threshold AT is applied whenever
`
`the measured oxygensaturation falls within range 650, extending from lower
`
`limit L, up to maximum value Max,suchas illustrated at segments 620, 630,
`
`and 640. Jd. at 6:15—30, 7:9-67, Fig. 5B (horizontal axis values extend from
`
`Lz to Max). The adaptive thresholds AT are constrainedto lie within
`
`range 660, extending from lowerlimit L2 up to limit Li. Jd. at 6:15-30,
`
`7:9-67, Fig. 5A (adaptive threshold AT line 442 is constrained between
`
`limits L; and L, along vertical axis).
`
`In a preferred embodiment, lower limit L2 is equal to the no delay
`
`alarm threshold ND, ofthe prior art system shownin Figure 1, and limit L;
`
`is equal to the delay alarm threshold D, of the prior art system. Jd. at
`
`5:66-6:4, 6:20-34. However,the fixed threshold the prior art implementsat
`
`limit L, is replaced by adaptive thresholds AT. /d. at 6:22—34. Each
`
`individual threshold AT, during a given time period suchas t), tz, or t3, may
`
`advantageously be implemented as a time delay alarm, asthepriorart
`
`system doeswithits fixed delay alarm threshold Dy. Jd. at 6:38—43.
`
`The system determinesa baseline B of the patient’s oxygen saturation
`
`during different time periods such ast), t2, and t3.
`
`/d. at 6:11—15, 6:44—7:8.
`
`For each different baseline B, the system applies a different adaptive alarm
`
`threshold AT. Jd. at 6:15-19, Fig. 6. Specifically, the system calculates
`
`delta A as a function of the varying baseline B andthe pre-set limits L; and
`
`L» and maximum value Max. Id. at 6:15—34 (describing Fig. 4A), 7:9-39
`
`(describing Fig. 5B). Then, the adaptive alarm thresholdis set at
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`AT =B-—A.Id. at 7:27-39 (describing Fig. 5A), 7:53—-8:6 (describing
`
`Fig. 6).
`
`C.
`
`The Claims ofthe ’218 Patent
`
`The ’218 patent lists seventeen claims, numbered 1—10 and 12-18.
`
`Ex. 1001, 1:4-9, 13:62-16:62. As a reissue patent, the claim listing in the
`
`°218 patent uses brackets to identify verbiage removed during the reissue
`
`process, andusesitalics to identify verbiage added during the reissue
`
`process. Jd. Dueto the extent and nature of these reissue amendments,it is
`
`difficult to ascertain the scope of the claimed invention by simply reviewing
`
`the claim listing in the ’218 patent, particularly in the three independent
`
`claims 1, 8, and 12. /d. at 13:62—16:62.
`
`Accordingly, we reproduce claim 1 here, removing the bracketed
`
`verbiage andnotitalicizing the added verbiage, to ease readability. We also
`include Petitioner’s labeling scheme 1(a)—1(i). See Pet. vii—viii.!
`
`[1(a)] 1. A system for reducing electronic alarmsin a
`medical patient monitoring system, the system comprising:
`[1(b)] an optical sensor configured to transmit optical
`radiation into a tissue site of a patient and detect attenuated
`optical radiation indicative of at least one physiological
`parameter of a patient; and
`
`' In other IPR proceedings, challenging other patents asserted by Patent
`Ownerin the District Court Litigation, Patent Ownerhas argued Petitioner
`uses abbreviation and spacingtricks to satisfy the Board’s word countlimits.
`Thesealleged tricks include citing to “EX 1X XX”instead of “Ex. 1xxx,” and
`omitting the full claim language, both of which Petitioner does here too. In
`the interest of fairness, Patent Owner may use these conventionsin
`preparing its Patent Owner Response. The parties also may use these
`conventionsfor any other briefing in this proceeding (e.g., Reply, Sur-reply,
`Motions to Exclude).
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`[1(c)] one or more hardwareprocessorsin electronic
`communication with the optical sensor, the one or more
`hardware processors configured to:
`
`[1(d)] determine oxygen saturation values of the
`patient overa first period of time;
`[1(e)] when at least one oxygensaturation value
`obtained overthe first period of time exceedsa first
`alarm threshold, determine whethera first alarm should
`be triggered;
`[1(f)] access a second alarm threshold to be
`applied during a second period of time subsequentto the
`first period of time, the second alarm threshold replacing
`the first alarm threshold,
`
`[1(g)] wherein the second alarm threshold has a
`value less than the at least one oxygen saturation value
`and greater than a lowerlimit and at an offset from the at
`least one oxygensaturation value, wherein the offsetis
`diminished as a difference betweentheat leastfirst
`oxygen saturation value and the lowerlimit diminishes;
`[1(h)] determine oxygen saturation values of the
`patient over the second period of time; and
`[1(i)] trigger a second alarm based onat least one
`value of the oxygen saturation values obtained overthe
`secondperiod of time exceeding the second alarm
`threshold.
`
`Ex. 1001, 13:62—14:40. Claim 12 recites a method comprising steps that are
`
`analogousto various system limitations of claim 1. See id. at 15:52-16:32.
`
`Claim 8 is a system claim somewhat akin to claim 1. See id. at
`
`15:1-39. Claim 8 differs from claim 1 most significantly in reciting that the
`
`processoris configured to “apply a time delay based on the second alarm
`
`threshold, wherein the time delay approaches zero as the at least one oxygen
`
`saturation value obtained overthefirst period of time approaches the lower
`
`limit.” Jd. at 15:19-23.
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`D.
`
`Prior Art and Asserted Grounds
`
`Petitioner asserts claims 1-10 and 12-18 are unpatentable, based on
`
`the following two grounds. See Pet. 5—6.
`
`
`
`Claims Challenged|35 U.S.C. §|References
`1-4, 7, 12-15
`
`
`5, 6, 8-10, 16-18
`Bock, Woehrle’, Kiani
`
`I. ANALYSIS
`
`A.
`
`Discretion to Deny Under 35 U.S.C. § 314(a)
`
`Patent Owner,relying on the Board’s precedential decisions in NHK°
`
`and the Fintiv Order, contends we should exercise our discretion under
`
`35 U.S.C. § 314(a) to deny institution based on the status of the District
`
`Court Litigation. See Prelim Resp. 13-19.
`
`1.
`
`Legal Standards
`
`Under35 U.S.C. § 314(a), the Director has discretion to deny
`
`institution of an inter partes review. Cuozzo Speed Techs., LLC v. Lee,
`
`136 S. Ct. 2131, 2140 (2016) (“[T]he agency’s decision to denya petition is
`
`a matter committed to the Patent Office’s discretion.”); SAS Inst. Inc. v.
`
`Tancu, 138 S. Ct. 1348, 1356 (2018) (“SAS”) (“[Section] 314(a) invests the
`
`Director with discretion on the question whetherto institute review.”
`
`2 Ex. 1005, U.S. Patent No. 7,079,035 B2, issued July 18, 2006.
`3 Ex. 1006, U.S. Patent No. 6,597,933 B2, issued July 22, 2003.
`4 Ex. 1007, WO 2009/093159 A1, published July 30, 2009.
`> NHKSpring Co., Ltd. v. Intri-Plex Techs., Inc., YPR2018-00752, Paper 8
`(PTAB Sept. 12, 2018) (precedential).
`
`8
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`(emphasis omitted)); Harmonic Inc. v. Avid Tech., Inc., 815 F.3d 1356, 1367
`
`(Fed. Cir. 2016) (“[T]he PTO is permitted, but never compelled,to institute
`
`an IPR proceeding.”).
`
`In determining whether to exercise discretion to deny institution under
`
`35 U.S.C. § 314(a), the Board considers an early trial date in related
`
`litigation as part of an assessmentofall relevant circumstancesofthe case,
`
`including the merits, in an effort to balance considerations such as system
`
`efficiency, fairness, and patent quality. Fintiv Order 5—6; see also NHK,
`
`Paper 8 at 19-20 (denyinginstitution relying, in part, on § 314(a) because
`
`the parallel district court proceeding was scheduledto finish before the
`
`Board reacheda final decision).
`
`Whenconsidering an early trial date in related litigation, the Board
`
`evaluates the following factors (““Fintiv factors”):
`
`3.
`
`1. whether the court granted a stay or evidence exists that one
`may be granted if a proceedingis instituted;
`2. proximity of the court’s trial date to the Board’s projected
`statutory deadline for a final written decision;
`investment in the parallel proceeding by the court and the
`parties;
`4. overlap between issues raised in the petition and in the
`parallel proceeding;
`5. whether the petitioner and the defendant
`proceeding are the same party; and
`6. other circumstances that
`impact
`discretion, including the merits.
`Fintiv Order 5—6. In evaluating these factors, “the Board takes a holistic
`
`in the parallel
`
`the Board’s exercise of
`
`view of whetherefficiency and integrity of the system are best served by
`
`denying orinstituting review.” Jd. at 6.
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`2.
`
`Factual Background
`
`The progress of the District Court Litigation is pertinent to discretion
`
`under 35 U.S.C. § 314(a).. We summarize the progress as follows.
`
`On June 12, 2019, Patent Ownerfiled a Complaint (Ex. 1008) against
`
`Petitioner in the U.S. District Court for the Southern District of California.
`
`Petitioner has filed a Motion to Stay the District Court Litigation (Ex. 1036)
`
`and Patent Owneropposed (Ex. 2001). Accordingto the parties, the District
`
`Court has not yet ruled on the Motion. See Prelim. Resp. 14-15; Prelim.
`
`Reply 2-3. The District Court has vacated all Markman deadlines, including
`
`the previously scheduled November3, 2020, Markmanhearing, pendingits
`
`decision on Petitioner’s Motion to Stay. See Ex. 1037.
`
`Patent Ownerservedits infringementcontentions on January 24,
`
`2020. Ex. 1016; see Prelim. Resp. 17. Petitioner servedits invalidity
`
`contentions on March 20, 2020, which were amended on September8, 2020.
`
`Exs. 2004 & 2007; see Prelim. Resp. 17.
`
`On June 11, 2020, Petitioner filed the Petition in this proceeding. See
`
`Paper4 (according the Petition a filing date of June 11, 2020).
`
`Per the court’s Scheduling Order, which was modified on October6,
`
`2020, fact discovery closes on February 12, 2021, and expert discovery
`
`closes on May 7, 2021. Ex. 2009, 3. The Scheduling Orderalso includes a
`
`trial date of November 30, 2021. Jd. at 4.
`
`Petitioner filed a stipulation in the District Court. Ex. 1038. The
`
`stipulation states that if the Board institutes inter partes review,Petitioner
`
`“will not pursue in [the District Court Litigation] the specific grounds
`
`[asserted in the inter partes review], or on any other ground. . . that was
`
`raised or could have been reasonably raised in an IPR(i.e., any ground that
`
`10
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`could be raised under §§ 102 or 103 on the basis ofprior art patent or printed
`
`publications).” Jd. at 6—7.
`
`3.
`
`Analysis ofthe Fintiv Factors
`
`With this background, we consider each ofthe factors set forth in the
`
`Fintiv Order. We then weigh the factors and take a holistic view of whether
`
`efficiency andintegrity of the patent system are best served by denying or
`
`instituting review.
`
`Factor 1:
`whethera stay exists or is likely to be granted ifa proceedingis instituted
`
`Petitioner has filed a Motion to Stay, but the District Court has notyet
`
`ruled on the motion. Prelim. Resp. 14-15; Prelim. Reply 2-3. Patent Owner
`
`contendsa “stay is unlikely.” Prelim. Resp. 14-15. In particular, Patent
`
`Ownercontends the Southern District of California has “found that direct
`
`competition betweenthe parties [in the relevant market] evidences
`significant prejudice weighing against a stay.” Jd. at 14 (citation omitted).
`Petitioner notes, however, that in the order vacating all Markman deadlines,
`
`the “[District] Court noted that any rescheduled Markman date may not be
`
`necessary, depending on howthe [District] Court rules on the motion to
`
`stay.” Prelim. Reply 3 (citing Ex. 1037).
`
`Becausethe District Court has not ruled on the pending motion to
`
`stay, we determinethis factor does not weigh for or against denying
`
`institution in this case. See Apple Inc. v. Fintiv, Inc., TPR2020-00019,
`Paper 15 at 12 (PTAB May13, 2020) (informative) (“Fintiv DI”); Sand
`
`Revolution II, LLC v. Cont’l Intermodal Group — Trucking LLC,
`
`11
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`IPR2019-01393, Paper 24 at 7 (PTAB June 16, 2020) (informative) (“Sand
`
`Revolution’).
`
`Factor 2:
`proximity ofthe court’s trial date to the Board’s projected statutory deadline
`
`As noted above,trial in the parallel proceeding currently is set to
`
`begin on November30, 2021. Ex. 2009, 4. Patent Owner contendsthistrial
`
`date “meansthereis little opportunity for efficiency or simplification with
`
`IPR proceedings becausethe final written decision date .
`
`.
`
`. will still come
`
`on oraftertrial.” Prelim. Sur-reply 3. Petitioner contends, on the other
`
`hand,that becausethe final written decision will issue close to the scheduled
`
`trial date, and all Markman deadlines have been indefinitely vacated, this
`
`factor strongly weighsin favorofinstituting inter partes review. Prelim.
`
`Reply 34. Petitioner also notes the District Court “has already amendedits
`
`case managementorder twice—including extendingthetrial date two
`
`months.” Jd. at 3.
`
`“If the court’s trial date is earlier than the projected statutory deadline,
`
`the Board generally has weighedthis fact in favor of exercising authority to
`
`deny institution under NHK.” Fintiv Order 9. Onthe other hand, “[i]f the
`
`court’s trial date is at or around the same time as the projected statutory
`
`deadline or even significantly after the projected statutory deadline, the
`
`decision whetherto institute will likely implicate other factors discussed
`
`herein, such as the resources that have been investedin the parallel
`
`proceeding.” Id.
`
`Here, the trial is scheduled to begin around the same time as our
`
`deadline to reach a final decision. Thus, we find that this factor does not
`
`weigh for or against denyinginstitution in this case.
`
`12
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`Factor 3:
`investmentin the parallel proceeding by the court andparties
`
`Patent Ownercontends“the parties and [District] Court have already
`
`invested substantial resourceslitigating .. . patent validity.” Prelim.
`
`Resp. 16-17. As noted above,the parties have already served their
`
`respective infringement contentions and invalidity contentions. However, as
`
`Petitioner points out, all Markman deadlines have been vacated, including
`
`the Markman hearing. Prelim. Reply 3-4. Moreover, much other work
`
`remainsin the District Court Litigation as it relates to invalidity: fact
`
`discovery is ongoing, expert reports are not yet due, and substantive motion
`
`practice is yet to come. Jd. Thus,althoughthe parties and the District Court
`
`have invested someeffort in the parallel proceeding to date, further effort
`
`remains to be expendedin this case before trial. The facts here are similar to
`
`those in both recent Board informative decisions. See Sand Revolution 11;
`
`Fintiv DI 14; see also Fintiv Order 10 (“If, at the time of the institution
`
`decision, the district court has not issued ordersrelated to the patentat issue
`
`in the petition, this fact weighs against exercising discretion to deny
`
`institution under NHK.”).
`
`The Fintiv Order also recognizes that “notwithstandingthat a
`
`defendanthas oneyearto file a petition, it may impose unfair costs to a
`
`patent ownerif the petitioner, faced with the prospect of a loomingtrialdate,
`
`waits until the district court trial has progressed significantly before filing a
`
`petition at the Office.” Fintiv Order 11. The Orderinstructs the parties to
`
`explain facts relevant to the Petition’s timing. Jd.; see also id. at 11-12
`(considering timing of the Petition as part of the third Fintiv factor). Patent
`Ownerasserts Petitioner “waited until the very end of the one-year period”
`
`13
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`to file its Petition, and argues the Petition “presents arguments that overlap”
`
`with Petitioner’s March 20, 2020,invalidity contentions in the District
`
`Court. Prelim. Resp. 16. Petitioner, on the other hand, contendsit “was not
`
`dilatory in filing this petition.” Prelim. Reply 5. Petitioner explains that the
`
`parties spent six months after the complaint was filed “engagedin settlement
`
`discussions.” Jd. Further, Petitioner notes that its initial invalidity
`
`contentions were filed on March 20, 2020, which was “concurrent with the
`
`nationwide shift to ‘work from home’ and the closing of counsels’ public
`
`offices.” Jd. Petitioner contendsthat, thereafter, it “diligently worked to
`
`draft IPR petitions challenging nine patents and 183 claims,” including the
`
`present Petition. Jd. Patent Owner respondsthat “[n]ormal settlement
`
`discussions .
`
`.
`
`. cannot excuse”the delay, and reiterates its contention that
`
`Petitioner waited “until just before the statutory deadline”to file its Petition.
`
`Prelim. Sur-reply 3.
`
`Petitioner filed the present Petition on June 11, 2020, almost three
`
`monthsafter servingits initial invalidity contentions on March 20, 2020, and
`
`two days before the statutory deadline of June 13, 2020. Based on thefacts
`
`present here, wefind Petitioner’s explanation for the timing of the Petition is
`
`reasonable, notwithstanding the closeness to the statutory deadline,
`
`particularly in view of the large numberof patents and claims challenged in
`
`this and Petitioner’s other related petitions for inter partes review, as well as
`
`the increased difficulty in preparing the Petitions due to concurrent office
`
`closures. See Prelim. Reply 5.
`
`Dueto the relatively limited investment in the District Court
`
`Litigation to date and the fact that the timing of the Petition was reasonable,
`
`14
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`wefind this factor weighs in favor of not exercising discretion to deny
`
`institution under 35 U.S.C. § 314(a).
`
`Factor4:
`overlap betweenissues raised in the petition andin the parallel proceeding
`
`Patent Ownercontends “Petitioner relies on the same combination of
`
`references, namely, Bock and Kiani,to allege invalidity of Claims 1-4,7,
`
`and 12-15 in the District Court [Litigation]’” and the present Petition.
`
`Prelim. Resp. 17; Exs. 2004 & 2007 (Invalidity Contentions).
`
`Petitioner notes the Petition “seeks review ofall claims of the
`
`[°218 patent], not merely those at issue in the [District Court Litigation].”
`Prelim. Reply 6; see also Ex. 2004, 1 (claims 1, 2, 3, 4, 7, 12, 13, 14, 15,
`and 18 of the ’218 patent are asserted in the District Court Litigation).
`
`Specifically, while Patent Owneris correct that the first ground of the
`
`Petition has also been presented for consideration by the District Court, the
`
`second groundof the Petition which attacks claims 5, 6, 8-10, and 16-18 of
`the °218 patent as having been obvious over Bock, Woehrle, and Kiani, has
`
`not been asserted in the District Court. See, e.g., Ex. 2004, 17; Ex. 2007, 17.
`
`Further, as noted above, Petitioner has filed in the District Court
`
`“a stipulation that, if IPR is instituted, [Petitioner] will not pursuein the
`District Court Litigation any groundraised or that could have been
`
`reasonably raised in an IPR.” Prelim. Reply 6; Ex. 1038. Petitioner
`contends that, becauseofthis stipulation,“there will be no overlap of
`invalidity issues between the [District Court Litigation] and [this inter partes
`
`review].” Prelim. Reply 6 (emphasis added).
`
`Patent Ownercontendsthe stipulation is “unclear” as to whether
`
`Petitioner reserves the right to proceed based on other referencescited in the
`
`15
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`invalidity contentions in District Court. Prelim. Sur-reply 4. We disagree
`
`with Patent Owner’s contention here. The portion of the stipulation quoted
`
`by Patent Owner,states that the “stipulation is not intended. . . to limit
`
`[Petitioner’s] ability to assert invalidity of the asserted claims .
`
`.
`
`. on any
`
`other ground(i.e., invalidity under §§ 101, 112).” Ex. 1038, 7 (emphasis
`
`added). Petitioner’s stipulation also unequivocally states, however, that it
`
`“will not pursue in this case the specific grounds. . . [in] the instituted inter
`
`parties [sic] review petition, or on any other ground .
`
`.
`
`. that was raised or
`
`could have been reasonably raised in an IPR (i.e., any ground that could be
`
`raised under §§ 102 or 103 on the basis ofprior art patents or printed
`
`publications).” Id. at 6-7 (emphasis added).
`
`Petitioner’s stipulation here mitigates any concerns of duplicative
`
`efforts between the District Court and the Board, as well as concerns of
`
`potentially conflicting decisions. See Sand Revolution 12. Importantly,
`
`Petitioner broadly stipulates not to pursue “any groundraised or that could
`have been reasonablyraised.” Prelim. Reply 6 (emphasis added). As noted
`in Sand Revolution, such a broadstipulation better addresses concerns of
`
`duplicative efforts and potentially conflicting decisions in a much more
`
`substantial way than a stipulation limited to “the ‘same grounds’ presented”
`
`in both proceedings. Sand Revolution 12 n.5. Accordingly, Petitioner’s
`
`broad stipulation ensures an inter partes review is “a true alternative to
`
`litigation.” Id.
`Thus, we find this factor weighs strongly in favor of not exercising
`discretion to deny institution under 35 U.S.C. § 314(a).
`
`16
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`Factor 5:
`whetherthe petitioner and the defendantin the parallelproceeding
`are the same party
`
`Petitioner and Patent Owner acknowledgethe parties are the same in
`
`this inter partes review proceeding andin the District Court Litigation.
`
`Prelim. Resp. 18; Prelim. Reply 6-7. Thus, this factor supports denying
`
`institution. See Fintiv DI 15; Sand Revolution 12-13; cf, Fintiv Order 13-14
`
`(“If a petitioner is unrelated to a defendantin an earlier court proceeding, the
`
`Board has weighedthis fact against exercising discretion.”).
`
`Factor 6:
`other circumstances and considerations that impact the Board’s exercise of
`discretion, including the merits
`
`Asdiscussed below,on this preliminary record, Petitioner has metits
`
`burden of demonstrating a reasonable likelihood that it would prevail in
`showing that claims of the ’218 patent are unpatentable.° Although we
`
`recognize the record may changeduringtrial, as discussed in detail below,
`
`Petitioner has madea sufficiently persuasive showing, on the record
`
`presently before us, that the prior art references cited in the Petition teach or
`
`suggestall limitations of the challenged claims. See Fintiv Order 14—15
`
`(discussing the merits of the Petition as a consideration).
`
`Wedeterminethis factor does not weigh for or against denying
`
`institution in this case.
`
`® The parties include argumentsdirected to the merits of the asserted
`groundsin their discussions of Factor 6. See Prelim. Reply 7; Prelim.
`Sur-reply 5-7. We do notrely on these arguments in our determination
`below that Petitioner has presented a reasonable likelihood of success on the
`merits (see infra Sections IIT.B-F).
`
`17
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`Conclusion
`
`Wetake “a holistic view of whetherefficiency and integrity of the
`
`system are best served by denying or instituting review” when considering
`
`the six Fintiv factors. Fintiv Order 6. Ourholistic review of the Fintiv
`
`factors, namely that the timing of the Petition was reasonable,the relatively
`
`limited investmentin the District Court Litigation to date, and that there is
`
`minimalpotential overlap of the two proceedings, indicates the Fintiv factors
`
`weighin favorofinstituting inter partes review. As such, weare not
`
`persuadedthe interests of efficiency and integrity of the system would be
`
`best served by invoking our authority under 35 U.S.C. § 314(a) to deny
`
`institution of a meritorious Petition. For the reasons discussed above, we
`
`decline to deny institution under § 314(a).
`
`B.
`
`Claim Construction
`
`Weinterpret the ’218 patent claims “using the same claim
`
`construction standard that would be used to construe the claim inacivil
`
`action under 35 U.S.C. 282(b).” 37 C.F.R. § 42.100(b) (2019). This
`
`“includ[es] construing the claim in accordance with the ordinary and
`
`customary meaning of such claim as understoodby oneofordinary skill in
`
`the art and the prosecution history pertaining to the patent.” Jd.
`
`Neither Petitioner nor Patent Owner proposes any express claim
`
`construction at this stage of the proceeding. See Pet. 10; Prelim. Resp. 12.
`
`However, after review of the assertions in the Petition and the Preliminary
`
`Response comparing claim 1 with Bock, we conclude two constructions of
`
`claim 1 are required, as follows.
`
`18
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`“at least one oxygen saturation value,”
`1.
`“the at least one oxygen saturation value,” and
`“the at leastfirst oxygen saturation value”’
`
`Claim 1 recites, in limitation 1(e), “at least one oxygen saturation
`
`value obtained overthe first period of time,” wherein the value “exceeds a
`
`first alarm threshold.” Ex. 1001, 14:6—8 (italicized emphasis added).
`
`Limitation 1(g) adds “the second alarm threshold has a value less than the at
`
`least one oxygen saturation value and greater than a lower limit and at an
`
`offset from the at least one oxygen saturation value, wherein the offsetis
`
`diminished as a difference betweenthe at leastfirst oxygen saturation value
`
`and the lower limit diminishes.” Jd. at 14:16—30 (italicized and underlined
`
`emphases, added).
`
`Applying routine claim construction principles, the references in
`
`limitation 1(g) to “the” at least one oxygen saturation value would normally
`
`be construed to refer back to the sameat least one oxygen saturation value
`
`previously recited in limitation 1(e). See, e.g., Microprocessor
`
`Enhancement Corp. v. Texas Instruments Inc., 520 F.3d 1367, 1375
`
`(Fed. Cir. 2008) (agreeing with District Court’s “initial assumption”“that
`
`wherea subsequent use of a claim term makesreferenceto the first use as an
`
`antecedent by using ‘said’ or ‘the,’” the term “should be construed
`
`consistently with its appearance in other places in the same claim”); Process
`
`Control Corp. v. HydReclaim Corp., 190 F.3d 1350, 1356-57 (Fed.Cir.
`
`1999) (“It is clear from the language of the claim itself that the term ‘a
`
`discharge rate’ in clause [b] is referring to the samerate as the term ‘the
`
`discharge rate’ in clause [d].”).
`
`At the sametime,“the patentee’s mere use of a term with an
`
`antecedent doesnot require that both terms have the same meaning.”
`
`19
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`Microprocessor, 520 F.3d at 1375. For example, the claimsat issue in the
`
`Microprocessordecision recited “at least one condition code,” and then
`
`referred back to “said condition code”or “the condition code”five times.
`
`Id. at 1370-72, 1375. The District Court had held the claims were
`
`“insolubly ambiguous for requiring that [‘condition code’] be interpreted
`
`differently in different portions of a single claim.” Jd. at 1374, 1375. In
`
`particular, the District Court had concluded“the term ‘condition code’ must
`
`meaneither a storage unit or a value derivedfrom the output ofthe storage
`
`unit depending onthe context in whichits used, yet [the] claims arefacially
`
`nonsensicalifeither ofthese definitions is used exclusively.” Id. at 1375
`
`(emphases added). The Federal Circuit agreed with the District Court’s
`
`reading ofthe claims, but nonetheless reversed the holding of indefiniteness,
`
`because “the appropriate meaning of ‘condition code’ is readily apparent
`
`from each occurrence in context.” Id. at 1375—76 (emphasis added). We
`
`conclude, on the present preliminary record, that claim 1 should be
`
`construed in the same fashion as the claims in the Microprocessor decision.
`
`In limitation 1(e), the “at least one oxygen saturation value”refers to
`
`one value of the patient data generated by the sensor during the first period
`
`of time. Such patient data is shown, for example, in Figure 6 of the
`
`°218 patent at parameter segments 620 and 630, during respective time
`
`periodst; and t2, where each segmentincludesa transient desaturation
`
`event 624 or 634 below a baseline B. Ex. 1001, 3:24—30 (describing Fig.3),
`
`7:41-64 (describing Fig. 6). Limitation 1(e) correspondingly recites that
`
`whenonevalue of the generated patient data obtained duringa first time
`
`period t; ortz reflects a desaturation event that exceeds(i.e., falls below) the
`adaptive alarm threshold AT for that time period, the processor determines
`
`20
`
`
`
`IPR2020-01078
`Patent RE47,218 E
`
`whetheran alarm should betriggered. Jd. at 7:40—-8:6. Thus, in
`
`limitation 1(e), the “at least one oxygensaturation value”refers to patient
`
`data generated by the sensor duringthefirst period of time.
`
`In limitation 1(g), we first conclude the tworecitations of “the at least
`
`one oxygen satur